Just a month ago, Jason Allen from the United States used the artificial intelligence of generative adversarial networks (GANs) artificial intelligence "Midjourney" to generate the painting "Space Opera House", which won the "Digital Art/Digital Retouching Photo" award
at the Colorado State Fair's fine art competition.
This is the second time that AI has come to the center of
the public eye after AlphaGo defeated South Korea's Lee Sedol in 2016.
At the same time, artificial intelligence using generative adversarial network technology like Midjourney is actively developing in many fields, including our common one-click face swapping, video repair, virus recognition, and even the AI pharmaceutical field
with higher barriers.
Insilico Medicine is an innovative drug discovery company
driven by end-to-end artificial intelligence (AI) that uses modern machine learning technologies such as generative adversarial networks (GANs), deep reinforcement learning (RL), and pre-trained models (Transformers) to connect generative biology, generative chemistry and clinical trial analysis 。 Since its establishment, it has built Pharma.
AI efficient AI drug discovery platform, including PandaOmics, a new target discovery engine, Chemistry42, a molecular design and generation platform, and InClinico, a clinical trial outcome prediction platform, focusing on and running through the three stages
of new drug development.
From artistic creation to drug discovery, what will machine learning technologies such as GANs bring to the pharmaceutical industry? At 19:30 on the evening of November 14, Insilico's AI expert team will join forces with Jensen Huang, founder and CEO of NVIDIA, Michael Antonov, co-founder of Oculus (acquired by Facebook in 2014), a well-known frostbite expert, and Professor Jeffrey D.
Rothstein of the Institute of Brain Science, Johns Hopkins University School of Medicine.
Jointly released new and upgraded Pharma.
AI platforms, including PandaOmics version 3.
0, Chemistry 42 version 2.
0 and the world premiere of inClinico
Rothstein of the Institute of Brain Science, Johns Hopkins University School of Medicine
Since 2021, with the support of its self-developed artificial intelligence platform, Insilico has efficiently discovered 8 preclinical drug candidates, including new compounds designed by AI for new targets, and new structural drug molecules
designed by AI based on specific properties for known targets.
Scan the QR code above to register for free and invite industry partners to witness the transformation
of AI-driven drug development.
About InsilicoAbout Insilico
Insilico is an end-to-end artificial intelligence (AI)-driven drug discovery company that connects biology, generative chemistry and clinical trial analysis through next-generation AI systems, leveraging modern machine learning technologies such as deep generative models, reinforcement learning, and transformational models to build a powerful and efficient AI drug discovery platform to identify novel targets and generate drug candidates with specific attribute molecular structures
Insilico focuses on areas of unmet medical need such as cancer, fibrosis, immunity, central nervous system diseases, and aging-related diseases, and promotes and accelerates the development of